METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS: ETIOLOGY, AT-RISK POPULATIONS AND TREATMENT


Creative Commons License

Hosgor-Limoncu M. , ERMERTCAN Ş., TAŞLI H. , ERAÇ B., YURTMAN A. N.

METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): ETIOLOGY, AT-RISK POPULATIONS AND TREATMENT, ss.329-364, 2010 (Diğer Kurumların Hakemli Dergileri) identifier identifier identifier

  • Basım Tarihi: 2010
  • Doi Numarası: 10.1128/aac.01902-17
  • Dergi Adı: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): ETIOLOGY, AT-RISK POPULATIONS AND TREATMENT
  • Sayfa Sayıları: ss.329-364

Özet

After beta-lactamase resistant antibiotics, including methicillin, nafcillin and cephalosporins had been introduced to the clinical use; the first methicillin-resistant Staphylococcus aureus (MRSA) isolates were described in 1961. Since then, MRSA clones have become a problem in health-care institutions throughout the world. Community acquired MRSA (CA-MRSA) isolates have also threatened human health for the last two decades. In multicentral surveillance studies, MRSA prevalence was determined as 1-2 % in North European countries but it may reach up to 80 % in some Far East countries.